Tag Archives: marker

KDHE, KDOR will not change gender marker policies for birth certificates, drivers’ licenses – KSNT News

  1. KDHE, KDOR will not change gender marker policies for birth certificates, drivers’ licenses KSNT News
  2. Transgender Kansas residents can keep updating their documents despite a new law, governor says Yahoo News
  3. Governor Kelly said Kansas will still allow trans residents to change driver’s licenses and birth certificates KAKE
  4. Gov. Laura Kelly says Kansas to allow gender marker changes, defying Kris Kobach analysis The Topeka Capital-Journal
  5. Doesn’t Kris Kobach have more to do than attack the tiny minority of trans Kansans? | Opinion Kansas City Star
  6. View Full Coverage on Google News

Read original article here

New Marker of ALS Outcome Identified

Summary: Using MEG neuroimaging, researchers have identified a new marker that can be used to predict the clinical outcomes for those suffering from ALS.

Source: Human Brain Project

A study by Human Brain Project (HBP) researchers has identified a new marker for predicting the clinical outcome of patients with Amyotrophic Lateral Sclerosis (ALS) through magnetoencephalography. This marker can be measured in the brain during its resting state and highlights the importance of brain flexibility for ALS patients.

The study has been led by the Institut de Neurosciences des Systèmes in Marseille, in collaboration with Consiglio Nazionale delle Ricerche, Parthenope University of Naples and Institute of Diagnosis and Care Hermitage Capodimonte in Naples, and the Monash University in Melbourne.

It was published online on Sept 30th, 2022, in Neurology, the medical journal of the American Academy of Neurology.

ALS is a neurodegenerative disease of the brain and spinal cord that causes loss of muscle control. The ability of moving, speaking and, eventually, breathing is progressively impaired. There is no known cure but treatments to improve symptoms, including magnetic stimulation, are being tested.

“The behaviour of the brain of an ALS patient is often hard to understand. The impairments can be caused by neuronal dysfunction of a small area of the brain that influences a much larger area, meaning you need whole brain scans to make predictions of the clinical outcome,” explains Pierpaolo Sorrentino from the INS, the last author of the study.

“Patients can struggle with motor tasks during the scans. This new method, instead, can be applied to the brain at rest, making it easier for the patients and more consistent.”

The researchers collected magnetoencephalography data on 42 ALS patients and 42 healthy controls at the University Parthenope in Naples, whose MEG facilities have recently become part of the EBRAINS network. 

The new study builds on previous work by the same group, which applied the methodology to Parkinson’s disease.

“A healthy brain is a flexible one, capable of reconfiguring itself to respond to stimuli, triggering neuronal avalanches across different areas,” adds Sorrentino.

“Think of it as a goalkeeper  waiting for a penalty kick. If you are fast enough, constantly moving rather than standing in the same place is a better strategy for being ready for most possible trajectories.”

“The neuronal avalanches spread in patterns which we can monitor with whole-brain scans,” explains Arianna Polverino of the Institute of Diagnosis and Care Hermitage Capodimonte, lead author of the study.

“We call the collection of all unique patterns the ‘functional repertoire’, a measurement of the flexibility of the brain.”

The researchers focused on quantifying the functional repertoire of ALS brains, even when the patient is unprompted and the brain is in a resting state.

ALS is a neurodegenerative disease of the brain and spinal cord that causes loss of muscle control. Image is in the public domain

“We found that a restriction of the functional repertoire corresponded to a more severe functional impairment. The more flexible the brain, the better the clinical outcome: the functional repertoire can be used as a reliable predictor of how the clinical outlook of a patient will likely evolve.”

“It is often difficult to tell how a particular therapy is working – now we might have a strong marker to predict its outcome,” says Sorrentino.

The next step, according to the scientists, is to use this non-invasive readout in a longitudinal study that tracks the evolution of the disease in a patient-specific way and adjust treatment accordingly.

See also

“The ultimate goal is to apply the predictive power of the functional repertoire in personalised medicine, perhaps extending the same approach to brain dynamics to other, large-scale applications,” concludes Polverino.

About this ALS research news

Author: Peter Zekert
Source: Human Brain Project
Contact: Peter Zekert – Human Brain Project
Image: The image is in the public domain

Original Research: Open access.
“Flexibility of Fast Brain Dynamics and Disease Severity in Amyotrophic Lateral Sclerosis” by Pierpaolo Sorrentino et al. Neurology


Abstract

Flexibility of Fast Brain Dynamics and Disease Severity in Amyotrophic Lateral Sclerosis

Background and Objectives: Amyotrophic lateral sclerosis (ALS) is a multisystem disorder, as supported by clinical, molecular and neuroimaging evidence. As a consequence, predicting clinical features requires a description of large-scale neuronal dynamics. Normally, brain activity dynamically reconfigures over time, recruiting different brain areas. Brain pathologies induce stereotyped dynamics which, in turn, are linked to clinical impairment. Hence, based on recent evidence showing that brain functional networks become hyper-connected as ALS progresses, we hypothesized that the loss of flexible dynamics in ALS would predict the symptoms severity.

Methods: To test this hypothesis, we quantified flexibility utilizing the “functional repertoire” (i.e. the number of configurations of active brain areas) as measured from source-reconstructed magnetoencephalography (MEG) in ALS patients and healthy controls. The activity of brain areas was reconstructed in the classical frequency bands, and the functional repertoire was estimated to quantify spatio-temporal fluctuations of brain activity. Finally, we built a k-fold cross validated multilinear model to predict the individual clinical impairment from the size of the functional repertoire.

Results: Comparing 42 ALS patients and 42 healthy controls, we found a more stereotyped brain dynamics in ALS patients (P < 0.05), as conveyed by the smaller functional repertoire. The relationship between the size of the functional repertoire and the clinical scores in the ALS group showed significant correlations in both the delta and the theta frequency bands. Furthermore, through a k-fold cross validated multilinear regression model, we found that the functional repertoire predicted both clinical staging (P < 0.001 and P < 0.01, in delta and theta bands, respectively) and symptoms severity (P < 0.001, in both delta and theta bands).

Discussion: Our work shows that: 1) ALS pathology reduces the flexibility of large-scale brain dynamics; 2) sub-cortical regions play a key role in determining brain dynamics; 3) reduced brain flexibility predicts disease stage as well as symptoms severity. Our approach provides a non-invasive tool to quantify alterations in brain dynamics in ALS (and, possibly, other neurodegenerative diseases), thus opening new opportunities in disease management as well as a framework to test, in the near future, the effects of disease-modifying interventions at the whole-brain level.

Read original article here

Retinal Test a New Prognostic Marker for Multiple Sclerosis Severity

Summary: Multiple sclerosis-associated retinal layer thinning predicts the severity of future relapses and the likelihood of disability.

Source: Medical University of Vienna

It is essential to assess the severity of multiple sclerosis (MS) in order to choose appropriate therapeutic measures, but this cannot be reliably done using existing methods.

A MedUni Vienna study now shows for the first time that the retina can be used as a prognostic marker.

Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and, hence, the likelihood of disability.

The results of the study have now been published in Neurology.

Researchers led by Gabriel Bsteh and Thomas Berger from the Department of Neurology at MedUni Vienna/University Hospital Vienna, working in collaboration with the Department of Ophthalmology and Optometrics at MedUni Vienna/University Hospital Vienna, studied 167 MS patients over a period of more than three years.

They hypothesized that retinal damage due to relapse reflects the extent of damage in the brain. As the scientific analyses confirmed, the loss of approximately 5 µm (micrometers) of retinal layer thickness after optic neuritis equates to a doubling of the risk of permanent disability after the next relapse.

These predictions could be used as the basis for treatment decisions in future: the results of the study suggest that more aggressive treatment is indicated where there is significant retinal layer thinning than would be the case for a smaller degree of thinning. This is true even if the patient has no disability or only slight disability at the time of measurement.

Prognostic technique already available

The researchers used optical coherence tomography (OCT) to measure retinal layer thickness. OCT is an imaging technique that uses infrared light to produce high-resolution three-dimensional images of very thin layers of tissue in the micrometer range (1 micrometer=1 thousandth of a millimeter). It is already used as a tool for diagnosing eye diseases such as glaucoma, and for evaluating disease progression.

Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and, hence, the likelihood of disability. Image is in the public domain

“The technique for predicting the course of MS is therefore already available to us,” said Gabriel Bsteh, first author of the study. “As we discovered in the course of our clinical trial, measurements should be taken at initial diagnosis, directly when optic neuritis occurs in relapsing MS, and six months thereafter.”

See also

The retina as a window to the brain

Multiple sclerosis is a chronic inflammatory autoimmune disease that leads to the loss of axons and neurons throughout the entire nervous system. Although this damage often goes unnoticed by patients at first, its extent determines the prognosis for the severity of the disease.

Since predictions about the course of the disease are important in MS for selecting the appropriate treatment, medical research has long been searching for reliable prognostic tools.

“In retinal layer thickness, we have found a new biomarker that represents a window to the brain, as it were,” said Gabriel Bsteh, summarizing the essence of the study. If the results are confirmed in larger follow-up studies, the technique could also be applied in routine clinical practice.

About this multiple sclerosis research news

Author: Press Office
Source: Medical University of Vienna
Contact: Press Office – Medical University of Vienna
Image: The image is in the public domain

Original Research: The findings will appear in Neurology

Read original article here

Theta Waves: A Marker of Emotional Regulation

Summary: Emotional regulation was linked to theta wave activity in the frontal cortex of the brain.

Source: University of Montreal

Without realizing it, we all rely on emotional regulation many times a day. It’s the process by which we mitigate the effect of disturbing stimuli in order to stay focused, improve our well-being and respond to demands from our environment.

Emotional regulation plays a key role in many mental illnesses and their treatment, including anxiety, mood disorders and borderline personality disorder.

Now Inès Zouaoui, a master’s student in psychology supervised by Professor Marc Lavoie at the Research Center of the Montreal Mental Health University Institute, has demonstrated that emotional regulation is associated with the action of theta waves in a specific part of the brain, the frontal cortex. Zouaoui is set to start her Ph.D. in biomedical science, psychiatry option, at UdeM this fall.

A brain wave specific to emotional regulation

Building on the results of a 2013 study that showed theta waves are generated during emotional regulation, the Montreal research team gave 24 subjects a cognitive reappraisal exercise.

“We used cognitive reappraisal, which basically involves re-interpreting the meaning of a situation, to carry out an experimental study of emotional regulation,” explained Zouaoui. “Our goal was to decipher the electrocortical mechanisms that accompany this complex process.”

They attached electrodes to the scalps of the 10 men and 14 women to record the electrical activity in their brains in response to upsetting images, such as a man armed with a knife or a threatening dog.

While their brain activity was being continuously measured and recorded using electroencephalography, the subjects were instructed to either increase, decrease or maintain their feelings of aversion, depending on what group they were assigned to. This step also involved cognitive reappraisal. After a few seconds, the image disappeared and the emotional regulation phase ended.

“We performed more detailed analyses of the encephalograms than what was done in the previous study to measure the frequencies of the brain waves generated during cognitive reappraisal and found only theta waves, which oscillate between 4 and 8 Hz,” Zouaoui reported.

“So theta waves can be considered a marker of emotional regulation.

“What’s new about our study is that by comparing the emotional induction and emotional regulation phases, we were able to show that theta waves are specific to the regulation phase,” said Zouaoui.

See also

The use of electrodes also enabled the research team to pinpoint the precise region of the brain responsible for generating the theta waves: the frontal regions involved in cognitive control. Image is in the public domain

“We also looked for alpha waves, which are in the 8 to 13 Hz range, to see if theta waves are specific to emotional regulation and found that alpha waves are not sensitive to either emotional induction or emotional regulation.”

The use of electrodes also enabled the research team to pinpoint the precise region of the brain responsible for generating the theta waves: the frontal regions involved in cognitive control.

New treatment options

Zouaoui’s goal wasn’t just to build on a previous study and add to the scientific literature; she hopes her experiment can one day be used to support clinical practice.

“Since theta waves can be a marker of successful emotional regulation, this could lead to new treatment options for people whose emotional regulation process is perturbed, which is the case in severe anxiety and schizophrenia, for example.”

About this emotional regulation research news

Author: Martin Lasalle
Source: University of Montreal
Contact: Martin Lasalle – University of Montreal
Image: The image is in the public domain

Read original article here

Blood marker identified for babies at risk of SIDS hailed as ‘breakthrough’

A newborn baby holds on a nurse’s finger at the maternity ward of the children hospital in Kabul, Afghanistan October 24, 2021. REUTERS/Jorge Silva/

Register now for FREE unlimited access to Reuters.com

Register

NEW YORK, May 13 (Reuters) – A team of Australian researchers have identified a biochemical marker in the blood that could help identify newborn babies at risk for sudden infant death syndrome (SIDS), a breakthrough they said creates an avenue to future tragedy-preventing interventions.

In their study, babies who died of SIDS had lower levels of an enzyme called butyrylcholinesterase (BChE) shortly after birth, the researchers said. BChE plays a major role in the brain’s arousal pathway, and low levels would reduce a sleeping infant’s ability to wake up or respond to its environment.

The findings are game changing and not only offer hope for the future, but answers for the past, study leader Dr. Carmel Harrington of The Children’s Hospital at Westmead in Australia said in a statement.

Register now for FREE unlimited access to Reuters.com

Register

“An apparently healthy baby going to sleep and not waking up is every parent’s nightmare and until now there was absolutely no way of knowing which infant would succumb,” Harrington said. “But that’s not the case anymore. We have found the first marker to indicate vulnerability prior to death.”

Using dried blood spots taken at birth as part of a newborn screening program, Harrington’s team compared BChE levels in 26 babies who later died of SIDS, 41 infants who died of other causes, and 655 surviving infants.

The fact that levels of the enzyme were significantly lower in the infants who subsequently died of SIDS suggests the SIDS babies were inherently vulnerable to dysfunction of the autonomic nervous system, which controls unconscious and involuntary functions in the body, the researchers said.

The Sydney Children’s Hospital Network in Australia called the discovery “a world-first breakthrough.”

A failure to wake up when appropriate “has long been considered a key component of an infant’s vulnerability” to SIDS, the research team said in The Lancet’s eBio Medicine.

SIDS is the unexplained death of an apparently healthy infant while asleep. Harrington lost her own child to SIDS 29 years ago and has dedicated her career to researching the condition, according to the statement.

Further research “needs to be undertaken with urgency” to determine whether routine measurement of BChE could potentially help prevent future SIDS deaths, the investigators said.

Register now for FREE unlimited access to Reuters.com

Register

Reporting by Nancy Lapid; Editing by Caroline Humer and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Theranos tests detected prostate-cancer marker in prostateless women

Enlarge / Former Theranos founder and CEO Elizabeth Holmes goes through security after arriving for court at the Robert F. Peckham Federal Building on September 17, 2021, in San Jose, California.

Around 2016, Theranos’ fourth lab director, Kingshuk Das, noticed a problem. He was analyzing data from the company’s diagnostic devices when he saw results from tests for prostate-specific antigen, or PSA. PSA is used to detect prostate cancer in men, and except in rare cases, it’s not present in women’s blood. Except, here it was, appearing in women’s test results.

Das took his PSA findings to CEO Elizabeth Holmes. “Females should generally not have PSA detectable,” Das told the jury in Holmes’ criminal trial yesterday. 

Yet Holmes refused to believe that Theranos’ proprietary devices could be at fault. She suggested that some of the patients whose blood was tested instead had a rare type of breast cancer, pointing to “an article or two” that showed it was possible, Das recalled. Holmes’ explanation, he told jurors, “seemed implausible.”

It was just one example of the many errors that Das encountered. He had been hired in March 2016, and when he first started, he thought the company was running tests on standard lab diagnostic equipment, not the company’s own Edison or MiniLab devices. He would soon discover that wasn’t true.

Immediate jeopardy

One of his primary tasks was responding to a devastating report the company received in January 2016 from the federal Centers for Medicare and Medicaid Services, or CMS. The report, which followed a November 2015 inspection, contained the header “CONDITION LEVEL DEFICIENCIES – IMMEDIATE JEOPARDY.”

“As a result of the survey, it was determined that your facility is not in compliance with all of the Conditions required for certification in the CLIA program,” the report read. “It was determined that the deficient practices of the laboratory pose immediate jeopardy to patient health and safety.”

As Das went through that report, a separate 121-page “statement of deficiencies” also produced by CMS, and the company’s own data, he reached a conclusion that called into question years of testing done on Theranos’ devices. 

“I found these instruments to be unsuitable for clinical use,” Das said in court. He ended up voiding every test Theranos had ever performed in its federally regulated lab, some 50,000 to 60,000 results from 2014 and 2015.

At the time, Holmes told Das that the problem wasn’t the instruments but rather quality control and quality assurance. Das wasn’t convinced. “These instruments were not performing from the very beginning,” he recalled telling Holmes. 

After the results were voided, Theranos never performed another test. Das continued to work for Theranos until he was laid off in 2018, shortly before the company was dissolved.

Das admitted that Theranos never contacted patients whose test results were voided.

Third lab director finishes testimony

Das’ testimony followed the cross-examination of former Theranos lab director Lynnette Sawyer by Holmes’ defense attorneys and redirect by the prosecution. Sawyer’s position was temporary, and she resigned in June 2015. Her job mostly involved using DocuSign to approve standard operating procedures (SOPs) for lab tests. She never set foot in the lab, and she half-heartedly tried to fix the SOPs when she spotted problems by emailing her contact at the company. Sawyer admitted to never calling anyone at Theranos to follow up on those changes.

Though Sawyer’s testimony yesterday was brief, it contained one juicy detail. One of Theranos’ calling cards was the nanotainer, the company’s name for a small vial that held blood obtained through finger pricks. Holmes would frequently pose for photos holding a nanotainer between her thumb and forefinger, including for a Forbes magazine cover. 

The term “nanotainer” appeared in one of the policies that Sawyer signed off on, so her answer to a question from Holmes’ defense attorney Lance Wade was a bit surprising. “What is a nanotainer?” he asked her. 

“I don’t know,” Sawyer replied.

Read original article here

2021 British Grand Prix FP1 report and highlights: Verstappen lays down a marker for qualifying after topping first practice at Silverstone

Ninety-thousand fans packed the Silverstone grandstands to witness Max Verstappen top first practice as the British Grand Prix weekend began under blue skies. McLaren’s Lando Norris bounced back from a tough week to take P2, ahead of fellow home racer Lewis Hamilton of Mercedes in P3, before this afternoon’s qualifying session.

As part of an experimental revised format this weekend, FP1 was the only hour-long session before qualifying at Silverstone, the result of which will set the grid for the inaugural F1 Sprint on Saturday afternoon. As a result, the teams wasted no time in getting on track, first on a mix of medium and hard tyres before switching to softs with around 20 minutes left.

READ MORE: Less practice, more jeopardy – The drivers prepare to step into the unknown with F1 Sprint at British GP

Red Bull racer Verstappen began on hard tyres and complained that his seatbelts were improperly fitted, but when he swapped for mediums he shot to the top of the timesheets with a benchmark of 1m27.745s. Switching to softs, he improved to 1m27.035s – 0.779s ahead of McLaren’s home racer Norris. Notably, Norris set his benchmark on medium tyres, rather than the soft.

Reigning champion Hamilton finished third on the softs, 0.780s off the pace in his upgraded Mercedes W12, while the Ferrari of Charles Leclerc filed in fourth. Hamilton’s team mate Valtteri Bottas took P5 and was 0.862s off the pace, ahead of Carlos Sainz in P6 – the Spaniard having spun at Turn 3 before setting his fastest lap.

1


Max
Verstappen
VER
Red Bull Racing

1:27.035

2


Lando
Norris
NOR
McLaren

+0.779s

3


Lewis
Hamilton
HAM
Mercedes

+0.780s

4


Charles
Leclerc
LEC
Ferrari

+0.793s

5


Valtteri
Bottas
BOT
Mercedes

+0.862s

Aston Martin’s Sebastian Vettel carries a new engine, turbo and MGU-H for this weekend onwards and made a late jump to seventh on softs, keeping Mexican Sergio Perez at bay in P8 for Red Bull.

BRITISH GRAND PRIX – Read the all-new digital race programme here

That left medium-shod Daniel Ricciardo ninth for McLaren, and with a new chassis and MGU-K, Esteban Ocon put his Alpine in P10 while team mate Fernando Alonso was 14th.

The AlphaTauris finished 11th and 12th, Pierre Gasly over a tenth faster than Yuki Tsunoda, with Alfa Romeo’s Antonio Giovinazzi 13th – his team mate Kimi Raikkonen 15th behind Alonso.

2021 British GP FP1: Sainz spins at Village

Haas’s Nikita Mazepin finished 19th, his team mate Mick Schumacher six-tenths ahead in P17. Between them was the Aston Martin of Lance Stroll, who said he was devoid of confidence with his car’s balance as the session came to a close.

Williams’ George Russell will be hoping that the crack in his mirror won’t prove to be foreboding as he rounded out the standings for Williams in P20, while team mate Nicholas Latifi took a solid P16.

MUST-SEE: Check out the teams’ 2021 liveries on the 2022 F1 car

With qualifying up next at 1800 local time, who will make history and start at the front for the first-ever F1 Sprint on Saturday? Stay tuned for live coverage and all the reaction over the 2021 British Grand Prix weekend.

Read original article here